United States: Federal Circuit Issues Its First Decision Interpreting BPCIA

Last Updated: July 23 2015
Article by Andrew D. Cohen and Irena Royzman

The courts must "say what the law is," even when that law, as Judge Lourie described the BPCIA, is "a riddle wrapped in a mystery inside an enigma."  Today, in Amgen Inc. v. Sandoz Inc., No. 2015-1499 (Fed. Cir. July 23, 2015),1 an historic case of first impression, a divided panel of the Federal Circuit for the first time did just that.  The court (per Judges Lourie and Chen) held that a biosimilar applicant can opt out of the BPCIA's patent dance provisions by withholding its abbreviated biologics license application (aBLA) and manufacturing information, and that the only consequence of doing so is being subject to a patent infringement action on any patent that could have been listed during the patent dance.  The court (per Judges Lourie and Newman) also held that a biosimilar applicant is required to provide a notice of commercial marketing under the BPCIA, and that such a notice can only be provided after the FDA has approved the biosimilar product.  In short, both reference product sponsors and biosimilar manufacturers will find good and bad news in today's decision.

Amgen v. Sandoz (which this blog has covered here, here, here, here, and here) is one of the first BPCIA lawsuits, and relates to Sandoz's recently-approved aBLA to market Zarxio (filgrastim-sndz), a biosimilar version of Amgen's Neupogen (filgrastim).  Last year, when FDA formally accepted its aBLA for review, Sandoz provided to Amgen a purported notice of commercial marketing, but otherwise refused to participate in the BPCIA's information exchange provisions (the first step in the patent dance).  Amgen sued Sandoz in the Northern District of California, alleging that Sandoz's actions violated the BPCIA and thereby violated California's unfair competition and conversion laws.  The district court decided that participating in the BPCIA's patent dance was optional, not mandatory, and that Sandoz's pre-approval notice of commercial marketing was effective.  This expedited appeal followed.

Today, as Judge Lourie put it, the Federal Circuit did its "best to unravel the riddle, solve the mystery, and comprehend the enigma" that is the BPCIA.  Judges Lourie and Chen first concluded that the BPCIA's information exchange provisions are optional.  Though recognizing that the plain language of 42 U.S.C. § 262(l)(2)(A) ("shall provide") is mandatory, the court reasoned that "[i]n other provisions, the BPCIA explicitly contemplates that a subsection (k) applicant might fail to disclose the required information by the statutory deadline," and those other provisions "indicate that 'shall' in paragraph (l)(2)(A) does not mean 'must.'"  Specifically, "the BPCIA does not specify any non-patent remedies for a failure to comply with paragraph (l)(2)(A)."  Rather, according to the court, paragraph (l)(9)(C) provides a "direct consequence of failing to comply with paragraph (l)(2)(A)"—a biosimilar applicant cannot bring a "declaratory judgment action on patents that claim the biological product or its use."  In such a situation, 35 U.S.C. § 271(e)(2)(C)(ii) provides an "artificial 'act of infringement'" of any patent "'that could be identified' pursuant to paragraph (l)(3)(A)(i)," and therefore a reference product sponsor, with little or no information about the biosimilar product, can bring a patent infringement lawsuit and "access the required information through discovery."  To the court, the contrary, namely "mandating compliance with paragraph (l)(2)(A) in all circumstances, would render paragraph (l)(9)(C) and 35 U.S.C. § 271(e)(2)(C)(ii) superfluous, and statutes are to be interpreted if possible to avoid rendering any provision superfluous."

Judges Lourie and Newman, in the next part of the opinion, concluded that "under paragraph (l)(8)(A), a subsection (k) applicant may only give effective notice of commercial marketing after the FDA has licensed its product."  This conclusion flowed from the statutory language, which refers to the subject of the notice of commercial marketing as "the biological product licensed under subsection (k)," while numerous other provisions of the statute refer to "'the biological product that is the subject of' the application, even when discussing its commercial marketing."  Awaiting FDA approval before providing a notice of commercial marketing made sense to the court because that is when "the product, its therapeutic uses, and its manufacturing processes are fixed," thereby allowing the reference product sponsor (RPS) "to effectively determine whether, and on which patents, to seek a preliminary injunction from the court."

Requiring that a product be licensed before notice of commercial marketing ensures the existence of a fully crystallized controversy regarding the need for injunctive relief.  It provides a defined statutory window during which the court and the parties can fairly assess the parties' rights prior to the launch of a biosimilar product.

In other words, as Judge Newman wrote in her concurrence on this issue, the notice of commercial marketing, which cannot be effective prior to FDA approval, "starts the 180-day stay of commercial marketing."

One of Sandoz's principal arguments against this reading was that this is tantamount to an extra six months of exclusivity above the 12 years expressly provided for by the BPCIA.  The court disagreed:  "That extra 180 days will not likely be the usual case, as aBLAs will often be filed during the 12-year exclusivity period for other products."  In other words, the 180-days will typically run concurrently with the 12 years of exclusivity.

Judges Lourie and Newman also held that a notice of commercial marketing is mandatory under the BPCIA.  Again, the court noted the use of mandatory language in the statute ("shall provide"), but here found no other BPCIA provision that "contemplates, or specifies the consequence for, noncompliance with paragraph (l)(8)(A) here."  The court explained that "[p]aragraph (l)(8)(A) is a standalone notice provision in subsection (l)," and "nothing in paragraph (l)(8)(A) conditions the notice requirement on paragraph (l)(2)(A) or other provisions of subsection (l)."  The court therefore maintained and extended the injunction it issued pending appeal to last through September 2, 2015 (180 days from the date Sandoz gave "effective" notice of commercial marketing after FDA approved Zarxio).

Judge Newman dissented from the majority on the question of whether the patent dance was mandatory.  She explained that the BPCIA uses plain and ordinarily-mandatory language ("shall") to require exchange of information—consistent with the intent of Congress to "initiate patent-related activity, to exchange relevant information, to facilitate negotiations, and to expedite any litigation."

Judge Chen disagreed that paragraph (l)(8)(A) is a standalone notice provision and, in his dissent, argued that the notice of commercial marketing was optional.

Today's decision will be dissected by both reference product sponsors and biosimilar manufacturers alike.  Whether the court will take this case up en banc—something both parties may seek given the split decision and its importance to litigation under the BPCIA—remains to be seen.

Footnote

1. Patterson Belknap represents Janssen Biotech in its amicus brief to the Federal Circuit supporting Amgen.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions